Trial Profile

Effect of pomalidomide on immune modulation at the time of early lymphocyte recovery in patients with AML

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomalidomide (Primary) ; Cytarabine; Daunorubicin; Etoposide
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Pharmacodynamics

Most Recent Events

04 Dec 2018 Results (n=51) assessing Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy for Acute Myeloid Leukemia and High-Risk Myelodysplasia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
22 Jan 2016 New trial record
08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com